secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2022-01-25T23:59:59+00:00
Accession:  0001564590-22-002321
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics amends supply agreement with EirGenix for trastuzumab biosimilar; up to $2M milestones
--------------------------------------------------------------------------------

- Amended supply agreement with EirGenix for bulk drug substance EG12014, a trastuzumab biosimilar used in BDC-1001 HER2 Boltbody ISAC.
- Requires joint steering committee, revised forecasting/order terms, and pricing adjustments based on production scale.
- Company to make up to $2.0M in milestone payments upon regulatory achievements for HER2 Boltbody ISAC.
- Agreement remains effective as long as Bolt or affiliates continue development/commercialization of the ISAC product.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000156459022002321/0001564590-22-002321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000156459022002321/bolt-8k_20220125.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-002321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer